Chimeric antigen receptor T cell therapy (CAR-T) has achieved significant success in treating hematological cancers like leukemia and lymphoma, but little success in treating solid tumors due to reduced function and limited persistence from expansion of these cells outside the patient’s body prior to reinfusion. Another factor is that current CAR-T therapy targets the same proteins on cancer cells that are expressed on normal cells, further reducing the efficacy of treatment as well as increasing the risk of cytokine release syndrome (CRS), a severe inflammatory and sometimes fatal complication associated with current FDA-cleared T cell immunotherapies. CDR3 Therapeutics (CDR3) has developed a stem cell-based therapy that overcomes the reduced functionality and persistence limitations of current therapies. Additionally, CDR3 therapies target viral proteins, avoiding the issues associated with targeting cellular proteins. Engrafting CDR3’s therapeutic cells in the patient’s bone marrow provides continuous. .
